---
figid: PMC8699317__biomolecules-11-01850-g005
figtitle: 'CD44: A Multifunctional Mediator of Cancer Progression'
organisms:
- NA
pmcid: PMC8699317
filename: biomolecules-11-01850-g005.jpg
figlink: /pmc/articles/PMC8699317/figure/biomolecules-11-01850-f005/
number: F5
caption: 'Cancer-associated signalling pathways modulated by CD44. CD44 can upregulate
  EMT biomarkers, Snail1 and Zeb1, promoting proliferation and invasion. CD44 activates
  KRAS through the MAPK pathway, hence promoting tumour cell proliferation and survival.
  CD44 mediates invasion and metastasis by binding to HER2, leading to the inhibition
  of miR-139 and upregulation of CXCR4. There is positive crosstalk between CD44 and
  FGFR2 to maintain cancer stemness. CD44 regulates tumour cell proliferation, invasion
  and migration by modulating c-Src via AKT/GSK-3β signalling. CD44/VCAM-1 interaction
  promotes invasion signalling by the ezrin/PI3K pathway. CD44 binds to HA, resulting
  in stemness development via the PI3K/4EBP1/SOX2 pathway. Also, the HA/CD44 interaction
  can drive tumour invasion, metastasis and stemness through Src activating RAS/FAK/ERK
  pathways. Similarly, HA/CD44 stimulates the PI3K/AKT signalling pathway to increase
  therapeutic resistance. CD44 can sustain EGFR and AKT signalling by inhibition of
  Rab7A, leading to therapeutic resistance. CD44 promotes the expression of HAS2 by
  activating the PI3K/AKT signalling pathway. HAS2 further enhances CD44-mediated
  PI3K/AKT signalling, thus creating a positive feedback loop that drives tumour cell
  resistance and survival. CD44 can stabilise the cystine/glutamate antiporter (xCT),
  leading to increased GSH and decreased ROS levels, which, in turn, results in tumour
  cell proliferation and therapeutic resistance mediated by suppression of the p38
  pathway. CD44 regulates tumour cell proliferation by the Wnt/β-catenin signalling
  pathway. CD44 can promote invasion and migration through the activation of the Hippo-YAP
  oncogene signalling pathway. CD44 mediates tumour cells resistance by upregulating
  Twist1 and AKT signalling. CD44-ICD binds to CREB, enhances S133 phosphorylation
  and enriches CREB recruitment to the cyclin D1 promoter, thus promoting cyclin D1
  activity, resulting in cell proliferation. CD44-ICD is released in a hypoxic environment
  and binds to HIF-2α leading to induced stemness. Abbreviations: EMT, epithelial–mesenchymal
  transition; HER2, human epidermal growth factor receptor 2; CXCR4, C-X-C chemokine
  receptor type 4; FGFR2, fibroblast growth factor receptor 2; EGFR, epidermal growth
  factor receptor; HAS2, hyaluronan synthase 2; GSH, glutathione; ROS, reactive oxygen
  species; CD44-ICD, CD44 intracellular domain; CREB, cAMP response element-binding;
  HIF-2α, hypoxia-inducible factors 2 alpha.'
papertitle: 'CD44: A Multifunctional Mediator of Cancer Progression.'
reftext: Malak Hassn Mesrati, et al. Biomolecules. 2021 Dec;11(12):1850.
year: '2021'
doi: 10.3390/biom11121850
journal_title: Biomolecules
journal_nlm_ta: Biomolecules
publisher_name: MDPI
keywords: CD44 | regulation | tumourigenesis | signalling pathways | prognosis | therapeutic
  targeting
automl_pathway: 0.6941728
figid_alias: PMC8699317__F5
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8699317__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8699317__biomolecules-11-01850-g005.html
  '@type': Dataset
  description: 'Cancer-associated signalling pathways modulated by CD44. CD44 can
    upregulate EMT biomarkers, Snail1 and Zeb1, promoting proliferation and invasion.
    CD44 activates KRAS through the MAPK pathway, hence promoting tumour cell proliferation
    and survival. CD44 mediates invasion and metastasis by binding to HER2, leading
    to the inhibition of miR-139 and upregulation of CXCR4. There is positive crosstalk
    between CD44 and FGFR2 to maintain cancer stemness. CD44 regulates tumour cell
    proliferation, invasion and migration by modulating c-Src via AKT/GSK-3β signalling.
    CD44/VCAM-1 interaction promotes invasion signalling by the ezrin/PI3K pathway.
    CD44 binds to HA, resulting in stemness development via the PI3K/4EBP1/SOX2 pathway.
    Also, the HA/CD44 interaction can drive tumour invasion, metastasis and stemness
    through Src activating RAS/FAK/ERK pathways. Similarly, HA/CD44 stimulates the
    PI3K/AKT signalling pathway to increase therapeutic resistance. CD44 can sustain
    EGFR and AKT signalling by inhibition of Rab7A, leading to therapeutic resistance.
    CD44 promotes the expression of HAS2 by activating the PI3K/AKT signalling pathway.
    HAS2 further enhances CD44-mediated PI3K/AKT signalling, thus creating a positive
    feedback loop that drives tumour cell resistance and survival. CD44 can stabilise
    the cystine/glutamate antiporter (xCT), leading to increased GSH and decreased
    ROS levels, which, in turn, results in tumour cell proliferation and therapeutic
    resistance mediated by suppression of the p38 pathway. CD44 regulates tumour cell
    proliferation by the Wnt/β-catenin signalling pathway. CD44 can promote invasion
    and migration through the activation of the Hippo-YAP oncogene signalling pathway.
    CD44 mediates tumour cells resistance by upregulating Twist1 and AKT signalling.
    CD44-ICD binds to CREB, enhances S133 phosphorylation and enriches CREB recruitment
    to the cyclin D1 promoter, thus promoting cyclin D1 activity, resulting in cell
    proliferation. CD44-ICD is released in a hypoxic environment and binds to HIF-2α
    leading to induced stemness. Abbreviations: EMT, epithelial–mesenchymal transition;
    HER2, human epidermal growth factor receptor 2; CXCR4, C-X-C chemokine receptor
    type 4; FGFR2, fibroblast growth factor receptor 2; EGFR, epidermal growth factor
    receptor; HAS2, hyaluronan synthase 2; GSH, glutathione; ROS, reactive oxygen
    species; CD44-ICD, CD44 intracellular domain; CREB, cAMP response element-binding;
    HIF-2α, hypoxia-inducible factors 2 alpha.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - sab
  - Abd-B
  - kra
  - kraken
  - Myd88
  - Src64B
  - ww
  - Akt
  - yki
  - Bro
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - ha
  - Fak
  - ras
  - Ras64B
  - Ras85D
  - Erk7
  - rl
  - htl
  - Rab7
  - twi
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - pag
  - SH3BP5
  - KRAS
  - NRAS
  - SRC
  - ITK
  - SLC22A3
  - PRAME
  - AKT1
  - AKT2
  - AKT3
  - CD44
  - ERBB2
  - YAP1
  - PTK2
  - HRAS
  - EPHB2
  - MAPK1
  - MAPK3
  - FGFR2
  - RAB7A
  - TWIST1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - HAS2
  - HAS1
  - SLC7A11
  - PRDX1
  - PAG1
---
